Invivyd outlines mid-2026 pivotal data timeline for VYD2311 as DECLARATION study reaches target enrollment
Source: SeekingAlpha
2026-03-05 11:26:54 ET
More on Invivyd
- Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript
- Invivyd rises as FDA agrees with late-stage trial design for COVID-19 therapy
- Invivyd granted FDA fast track status for COVID therapy
- Seeking Alpha’s Quant Rating on Invivyd
- Historical earnings data for Invivyd
Read the full article on Seeking Alpha
For further details see:
Invivyd outlines mid-2026 pivotal data timeline for VYD2311 as DECLARATION study reaches target enrollment
Invivyd Inc.
NASDAQ: IVVD
IVVD Trading
9.86% G/L:
$1.895 Last:
852,583 Volume:
$1.79 Open:
IVVD Latest News
March 05, 2026 07:03:00 am
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates
March 05, 2026 07:01:00 am
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer
IVVD Stock Data
$379,990,219
86,954,817
0.02%
28
N/A
Biotechnology & Life Sciences
Healthcare
US
New Haven
